131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

December 31, 2026

Conditions
DIPG
Interventions
DRUG

131I-Omburtamab

Omburtamab is a murine IgG1 monoclonal antibody, recognizing CD276 (also known as B7-H3).

DEVICE

Convention Enhanced Delivery

The planned intervention includes surgical placement of a small caliber cannula into the tumor located in the pons using standard stereotactic techniques followed by CED of 131Iomburtamb.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Labcorp Corporation of America Holdings, Inc

INDUSTRY

collaborator

Invicro

OTHER

lead

Y-mAbs Therapeutics

INDUSTRY